Conmed (CNMD) Tops Q4 EPS by 11c, provides guidance

Conmed (NYSE: CNMD) reported Q4 EPS of $1.43, $0.11 better than the analyst estimate of $1.32. Revenue for the quarter came in at $373.2 million versus the consensus estimate of $366.97 million.

GUIDANCE:

Conmed sees FY2026 EPS of $4.30-$4.45, versus the consensus of $4.42. Conmed sees FY2026 revenue of $1.345-1.375 billion, versus the consensus of $1.369 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
• Alphabet (GOOGL) Reiterated at Market Outperform by Citizens amid VP Engineer Transition